Severe and resistant palmar psoriasis successfully treated with risankizumab

被引：3
作者：
Calabrese, Laura [1 ,2 ]
Caldarola, Giacomo [1 ,2 ]
Peris, Ketty [1 ,2 ]
Simone, Clara De [1 ,2 ]
机构：
[1] Sacred Heart Catholic Univ, Inst Dermatol, Largo F Vito 1, I-00168 Rome, Italy
[2] IRCCS A Gemelli Univ Polyclin Fdn, Rome, Italy
来源：
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 157卷 / 01期
关键词：
D O I：
10.23736/S2784-8671.21.06972-8
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：118 / 119
页数：2
相关论文
共 5 条
[1]   Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial [J].
Blauvelt, Andrew ;
Leonardi, Craig L. ;
Gooderham, Melinda ;
Papp, Kim A. ;
Philipp, Sandra ;
Wu, Jashin J. ;
Igarashi, Atsuyuki ;
Flack, Mary ;
Geng, Ziqian ;
Wu, Tianshuang ;
Camez, Anne ;
Williams, David ;
Langley, Richard G. .
JAMA DERMATOLOGY, 2020, 156 (06) :649-658
[2]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[3]   Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials [J].
Gordon, Kenneth B. ;
Strober, Bruce ;
Lebwohl, Mark ;
Augustin, Matthias ;
Blauvelt, Andrew ;
Poulin, Yves ;
Papp, Kim A. ;
Sofen, Howard ;
Puig, Lluis ;
Foley, Peter ;
Ohtsuki, Mamitaro ;
Flack, Mary ;
Geng, Ziqian ;
Gu, Yihua ;
Valdes, Joaquin M. ;
Thompson, Elizabeth H. Z. ;
Bachelez, Herve .
LANCET, 2018, 392 (10148) :650-661
[4]   A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic [J].
Hansel, K. ;
Zangrilli, A. ;
Bianchi, L. ;
Peris, K. ;
Chiricozzi, A. ;
Offidani, A. ;
Diotallevi, F. ;
Fargnoli, M. C. ;
Esposito, M. ;
Amerio, P. ;
Gualdi, G. ;
Bianchi, L. ;
Stingeni, L. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (03) :E169-E170
[5]   Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial [J].
Reich, Kristian ;
Gooderham, Melinda ;
Thaci, Diamant ;
Crowley, Jeffrey J. ;
Ryan, Caitriona ;
Krueger, James G. ;
Tsai, Tsen-Fang ;
Flack, Mary ;
Gu, Yihua ;
Williams, David A. ;
Thompson, Elizabeth H. Z. ;
Paul, Carle .
LANCET, 2019, 394 (10198) :576-586
1